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Summary
 
Differential genomic DNA methylation has the potential to influence the development of T
cell cytokine production profiles. Therefore, we have conducted a clonal analysis of interferon
(IFN)-
 
g
 
 and interleukin (IL)-3 gene methylation and messenger (m)RNA expression in pri-
mary CD8
 
1
 
 T cells during the early stages of activation, growth, and cytokine expression. De-
spite similar distributions and densities of CpG methylation sites, the IFN-
 
g
 
 and IL-3 promot-
ers exhibited differential demethylation in the same T cell clone, and heterogeneity between
clones. Methylation patterns and mRNA levels were correlated for both genes, but demethyla-
tion of the IFN-
 
g
 
 promoter was widespread across 
 
.
 
300 basepairs in clones expressing high
levels of IFN-
 
g
 
 mRNA, whereas demethylation of the IL-3 promoter was confined to specific
CpG sites in the same clones. Conversely, the majority of clones expressing low or undetect-
able levels of IFN-
 
g
 
 mRNA exhibited symmetrical methylation of four to six of the IFN-
 
g
 
promoter CpG sites. Genomic DNA methylation also has the potential to influence the main-
tenance or stability of T cell cytokine production profiles. Therefore, we also tested the herita-
bility of IFN-
 
g
 
 gene methylation and mRNA expression in families of clones derived from
resting CD44
 
low
 
CD8
 
1
 
 T cells or from previously activated CD44
 
high
 
CD8
 
1
 
 T cells. The pat-
terns of IFN-
 
g
 
 gene demethylation and mRNA expression were faithfully inherited in all
clones derived from CD44
 
high
 
 cells, but variable in clones derived from CD44
 
low
 
 cells. Overall,
these findings suggest that differential genomic DNA methylation, including differences among
cytokine genes, among individual T cells, and among T cells with different activation histories,
is an important feature of cytokine gene expression in primary T cells. 
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D
 
ifferential cytokine gene expression in activated T
lymphocytes plays an important part in the diversifi-
cation of T cell cytokine production patterns and polariza-
tion towards type 1, type 2, and other profiles (1–4). The
underlying molecular mechanisms are likely to operate
combinatorially, involving a number of pretranscriptional,
transcriptional, and posttranscriptional levels of control
with multiple interacting factors at each level (5–7).
At the pretranscriptional/transcriptional level, the in-
volvement of genomic DNA methylation in the regulation
of differential cytokine gene expression has not yet been
widely investigated. In other systems, methylation of the
cytosine residue in CpG dinucleotides can be a negative
regulatory influence on the expression of various inducible
tissue-specific genes (8–10). Off-on effects occur when
CpG methylation influences chromatin conformation and
accessibility (11, 12). In addition, quantitative influences on
gene expression are possible since methylation can differen-
tially inhibit the binding of individual transcription factors,
directly via the protruding methyl group or indirectly via
methyl-CpG–binding proteins (13–15). Importantly, the
methylation status of CpG sites can be heritable, thus con-
tributing to epigenetic regulation of gene expression (16).
Only a few studies have examined the role of DNA me-
thylation in cytokine gene expression in leukocytes. Inhibi-
tion of DNA methylation has been used to establish consti-
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tutive IL-2 secretion in EL-4 thymoma clones (17).
Reduced CpG methylation in the TNF-
 
a
 
 promoter has
been described in myeloid leukemia cells and differentiated
monocyte cell lines expressing TNF-
 
a
 
 mRNA (18, 19).
Differences in IFN-
 
g
 
 expression among long-term T cell
clones, T cell lines, and primary human T cell populations
have been found to be associated with differential CpG
methylation in this gene (20–22). The latter important
findings are supported by data on methylation-mediated al-
terations in transcription factor–binding to the proximal
IFN-
 
g
 
 promoter element (23). Whether heritable methyla-
tion patterns in the IFN-
 
g
 
 gene can account for the stabil-
ity of augmented IFN-
 
g
 
 expression in memory/effector T
cells, for example, has not yet been tested.
Until recently, analysis of genomic DNA methylation
has generally required relatively large amounts of DNA for
methylation-dependent restriction endonuclease digestion
followed by Southern blotting– or semi-quantitative PCR–
based evaluation of restriction patterns. These approaches
have been largely superseded by the development of a
PCR- and DNA sequencing–based method for positive
display of methylated cytosine residues: bisulfite genomic
sequencing (24, 25). This method allows evaluation of the
methylation status of all cytosine residues on both DNA
strands, regardless of their restriction enzyme recognition
context. In addition, PCR amplification of bisulfite-modi-
fied DNA from small numbers of cells allows clonal analy-
ses (26).
In this investigation, we have applied bisulfite genomic
sequencing to analyze the methylation patterns of the
mouse IFN-
 
g
 
 and IL-3 genes during development of
short-term CD8
 
1
 
 T cell clones from normal animals. We
have also coupled the methylation studies to quantitative
competitive PCR (QCPCR)
 
1
 
 analyses of IFN-
 
g
 
 and IL-3
mRNA expression. To our knowledge, this is the first re-
port of this combination of analyses for any cytokine gene
in any type of leukocyte. The bisulfite sequencing results
extend the previous findings for one CpG site in the IFN-
 
g
 
promoter to cover all of the other IFN-
 
g
 
 promoter methy-
lation sites, and provide entirely new information for all of
the methylation sites in the IL-3 promoter.
The results show that, despite similar distributions and
densities of CpG methylation sites, the IFN-
 
g
 
 and IL-3
promoters exhibit differential demethylation in the same T
cell clone. The coupled methylation QCPCR results show
that demethylation of the IFN-
 
g
 
 and IL-3 genes is inti-
mately associated with differential expression of these two
cytokines in activated CD8
 
1
 
 T cell clones. The pattern of
IFN-
 
g
 
 promoter demethylation is widespread and compat-
ible with regulatory mechanisms based on altered chroma-
tin conformation. In contrast, the pattern of IL-3 promoter
demethylation is more site specific and focussed on se-
quence elements and transcription factor–binding sites ad-
ditional to those currently studied. Thus, differential meth-
ylation patterns among cytokine genes and among primary
T cell clones suggest that DNA methylation may be one of
the mechanisms that underpins the generation of diversity
in T cell cytokine profiles during primary immune re-
sponses. Furthermore, we show that both IFN-
 
g
 
 gene me-
thylation patterns and mRNA expression levels are herita-
ble in the subclones derived from CD44
 
high
 
CD8
 
1
 
 (recently
activated or memory/effector) cells, but variable among the
offspring derived from CD44
 
low
 
CD8
 
1
 
 (resting or naive)
cells. This indicates that heritable gene methylation patterns
correlate with CD44 and IFN-
 
g
 
 expression and thus have
the potential to serve as molecular markers of memory/ef-
fector T cells. Together, these results suggest a role for gene
methylation in establishing and/or maintaining differential
cytokine gene expression patterns in primary T cells.
 
Materials and Methods
 
Mouse Lymphocyte Preparation.
 
Specific pathogen–free female
C57BL/6 mice (Animal Resources Centre, Murdoch, Western
Australia) were used when 6–12 wk old. CD8
 
1
 
 T cells were iso-
lated from pooled brachial, axillary, cervical, inguinal, para-aortic,
and mesenteric LNs as previously described (27). In brief, LN
cells were stained with PE-conjugated rat anti–mouse CD4 mAb
(GK1.5), FITC-conjugated rat anti–mouse CD8 mAb (53.6-7),
and 0.5 
 
m
 
g/ml propidium iodide. In some experiments, the stain-
ing with anti-CD4 mAb was substituted with biotinylated anti-
CD44 mAb (IM7.8.1) followed by PE-conjugated streptavidin.
Fluorescence-activated cell sorting was conducted using a FACS
 
Ò
 
Vantage flow cytometer with Lysis II software (Becton Dickin-
son, Sunnyvale, CA). Viable CD8
 
1
 
 cells were positively sorted
and, upon reanalysis, were 
 
.
 
97% pure in all experiments. In
some experiments, the CD44
 
low
 
 and CD44
 
high
 
 subsets of the
CD8
 
1
 
 population were also separated by sorting for the lowest or
highest 15%, respectively, of the staining distribution. On a four-
decade scale, the reanalyzed sorted CD44
 
low
 
 cells were contained
within the first decade with a mean fluorescence intensity of 4.6,
whereas the sorted CD44
 
high
 
 cells were within the third decade
with a mean intensity of 192. For clonal cultures, single CD8
 
1
 
 T
cells were then seeded directly into the wells of prepared (see be-
low) 60-well Terasaki tissue culture plates (Nunc, Roskilde,
Denmark) using the automated cell deposition unit of the flow
cytometer.
 
Accessory Cell–free CD8
 
1
 
 T Lymphocyte Culture.
 
Terasaki and
96-well flat-bottomed tissue culture plates were coated with a
mixture of hamster anti–mouse CD3
 
e
 
 mAb (145-2C11) at 10
 
m
 
g/ml, rat anti–mouse LFA-1 mAb (I21/7.7) at 5 
 
m
 
g/ml, and rat
anti–mouse CD8 mAb (53.6-7) at 10 
 
m
 
g/ml diluted in PBS. In
the presence of IL-2, this mAb combination activates CD8
 
1
 
 T
cells in a TCR-dependent manner without accessory cells, and
yields cloning frequencies of 75% for CD8
 
1
 
 cells from LNs of
normal mice (27, 28). After 12–16 h at 37
 
8
 
C, the coated plates
were washed once with PBS and twice with modified DMEM
supplemented with 216 mg/liter 
 
l
 
-glutamine, 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME,
antibiotics, and 10% heat-inactivated FCS (CSL Ltd., Parkville,
Victoria, Australia). Bulk T cell cultures were initiated at 10
 
4
 
cells/well in 200 
 
m
 
l of supplemented DMEM with 10% FCS, 600
IU/ml human 
 
r
 
IL-2 (Cetus Corp., Emeryville, CA), and varying
doses of fresh 5-azacytidine (see below). For clonal cultures, after
automated deposition of single T cells into Terasaki plates, addi-
 
1
 
Abbreviations used in this paper:
 
 AP, activator protein; ATF, activating
transcription factor; CREB, cyclic AMP response element binding pro-
tein; QCPCR, quantitative competitive PCR. 
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tional medium was placed in each well to attain final concentra-
tions of 15% FCS and 600 IU/ml IL-2. Subcloning was per-
formed by micromanipulation (27, 29) after 4 d of stimulation
and the parent clones and subclones were harvested 2–3 d after
micromanipulation.
 
Secreted Cytokine Assays.
 
Supernatants harvested from bulk
CD8
 
1
 
 T cell cultures after varying periods of stimulation were as-
sayed for IL-3 by FDC-P1 reporter cell assay as previously de-
scribed in detail (27). Appropriate controls demonstrated that the
presence of 5-azacytidine did not interfere with this bioassay at
the dilutions where titration end points were determined (data
not shown). Supernatant IFN-
 
g
 
 levels were quantitated using
ELISA kits (Endogen Inc., Cambridge, MA).
 
Genomic DNA and Cytoplasmic RNA Extraction and cDNA Syn-
thesis.
 
Nucleic acids were extracted using a combination of
published methods (30–32). After supernatant removal, T cell
clones were resuspended in 11 
 
m
 
l of lysis buffer (0.2 
 
3
 
 PBS, 20
 
m
 
g/ml oligo-dT [Boehringer Mannheim, Castle Hill, New South
Wales, Australia], 1% NP-40, 4 mM dithiothrietol, 4 U/ml
RNasin [Promega Corp., Madison, WI], 100 
 
m
 
g/ml tRNA
[Boehringer Mannheim]) and snap frozen at 
 
2
 
70
 
8
 
C. Nuclei were
pelleted and the supernatants were removed for cDNA synthesis
while the pellets were processed for DNA extraction. For cDNA
synthesis, supernatants were heated to 70
 
8
 
C for 5 min before ad-
dition of 14 
 
m
 
l of cDNA buffer (36 mM (NH
 
4
 
)
 
2
 
SO
 
4
 
, 134 mM
Tris HCl [pH 9], 0.018% Tween, 8.6 mM MgCl
 
2
 
, 0.7 mM
dNTPs, 1.4 mM dithiothrietol, 0.7 U/ml RNasin, and 0.14 U/ml
AMV reverse transcriptase [Promega Corp.]) and incubation at
42
 
8
 
C for 2 h. For genomic DNA isolation, nuclei were resus-
pended in 100 
 
m
 
l of GIT buffer (4 M guanidinium isothiocyan-
ate, 25 mM sodium acetate, 0.84% 2-ME, 10 
 
m
 
g/ml glycogen
[Boehringer Mannheim], and 5 
 
m
 
g/ml 
 
l
 
 DNA [Promega Corp.]),
and the DNA was precipitated with isopropanol. After centrifu-
gation at 14,000 
 
g
 
 for 30 min at 4
 
8C, the precipitates were
washed twice with 75% ethanol, air-dried and resuspended in 20
ml of water.
Bisulfite Modification of Genomic DNA. Genomic DNA was bi-
sulfite-treated using a method optimized for small cell numbers
(26). In brief, extracted genomic DNA was sheared by pipetting
and then denatured in 0.3 N NaOH for 20 min at 758C. Fresh
4.8 M sodium metabisulfite (pH 5.0) was prepared by adding 4.55 g
of Na2S2O5 and 0.4 ml of 10 N NaOH to 8.2 ml H2O and mix-
ing gently. To each 22-ml sample of denatured genomic DNA,
250 ml of 4.8 M Na2S2O5, 14 ml of fresh 10 mM hydroquinone,
and paraffin oil were added and the samples were incubated at
558C, shielded from light, for 4 h. Modified DNA was then puri-
fied using GenecleanÒ kits (BIO 101, La Jolla, CA), and des-
ulfonated in 0.3N NaOH at 378C for 20 min. Desulfonated
DNA was precipitated with ammonium acetate and ethanol, pel-
leted, washed with 70% ethanol, and resuspended in 20 ml H2O.
PCR and Sequencing of Bisulfite-modified Genomic DNA. Prim-
ers flanking CpG sites in the mouse IFN-g and IL-3 promoters
and specific for either the coding or noncoding strands of the
bisulfite-modified genomic DNA (Table 1) were designed using
the OLIGOTM program (Bresatec, Thebarton, South Australia)
and the following criteria in addition to those previously reported
Table 1. PCR and Sequencing Primers for Bisulfite-modified Genomic DNA
Primer Sequence (59 to 39) Position/strand* Use
MIFNGBIS1 ggtgtgaagtaaaagtgtttttagagaattttat 2262/coding 1st and 2nd round PCR, sequencing
MIFNGBIS2 tagagaattttataagaatggtataggtgggtat 2241/coding 2nd round PCR, sequencing
MIFNGBIS3 ccataaaaaaaaactacaaaaccaaaatacaata 1159/coding 2nd round PCR, sequencing
MIFNGBIS4 caataacaaccaaaaacaaccataaaaaaaaact 1179/coding 1st round PCR
MIFNGBIS5 ataaaattatagttgtaatgt 2149/coding Sequencing
MIFNGBIS6 cttctatctcaaatcaaaaaatc 177/coding Sequencing
MIFNGBIS7 gttagaaatagttatgaggaagagttgtaaagtt 1170/noncoding 1st and 2nd round PCR, sequencing
MIFNGBIS8 taggaggagaagtttagaatttttgttttaagtt 196/noncoding 2nd round PCR, sequencing
MIFNGBIS9 acaatttccaacccccaccccaaataatataaaa 2287/noncoding 2nd round PCR, sequencing
MIFNGBIS10 acaaaaactccctatactatactctataaataaa 2360/noncoding 1st round PCR
MIL3BIS1 ggctgtatagttagggttaagtttgtgtaagg 2337/coding 1st round PCR
MIL3BIS2 gatggtaggatgagattttattgtatagaaagt 2306/coding 2nd round PCR, sequencing
MIL3BIS3 acctacaccaaaccaacctcaaccaattactc 1228/coding 2nd round PCR, sequencing
MIL3BIS4 cataaaactcactaacttaaaacacctattaaaac 1265/coding 1st round PCR
MIL3BIS5 aagaagatggtttttgaataa 2203/coding Sequencing
MIL3BIS6 aacatcaaaaacaaaaacaac 188/coding Sequencing
MIL3BIS7 tacataaaaaacccaaatactcaaaaccaaac 2284/noncoding 1st and 2nd round PCR, sequencing
MIL3BIS8 aataacctttaaataaacaatctttcttcccata 2198/noncoding 2nd round PCR, sequencing
MIL3BIS9 gttattgattgaagtttggagttttaggtggaa 1122/noncoding 2nd round PCR, sequencing
MIL3BIS10 ggttaattttagttagttatttattgggagtttt 1217/noncoding 1st round PCR
*Position relative to transcription start site; strand refers to the specificity of the primer for the coding or noncoding strand of bisulfite-modified ge-
nomic DNA.106 Differential IFN-g and IL-3 Gene Methylation in CD81 T Cells
(25): (a) % G 1 C . 25%; (b) homopolymer strings ,9 bases; (c)
predicted C to T conversions .25% with a high density of con-
versions at the 39 primer end; (d) .508C predicted annealing
temperature; and (e) no false priming within the predicted PCR
product. Careful primer design was the most important require-
ment for specific amplification of bisulfite-modified DNA. Phos-
phodiester oligodeoxynucleotide primers were obtained com-
mercially (GIBCO BRL, Gaithersburg, MD).
25 ml PCR reactions were assembled using 0.3 U/tube Red
Hot polymerase (Advanced Biotechnologies, Leatherhead, Sur-
rey, UK) with the reaction buffer supplied by the manufacturer
(1.5 mM MgCl2, 200 mM dNTPs, 100 ng of each PCR primer,
1–4 ml bisulfite-modified DNA, and 50 ml paraffin oil). At least
20% of each set of reactions were negative control tubes lacking
template DNA. The reactions were amplified in an Omnigene
thermal cycler (Hybaid, Teddington, Middlesex, UK) using a
touchdown strategy (decreasing annealing temperatures from 59
to 528C in 18C increments with two cycles per increment, and a
final annealing temperature of 508C for 30 cycles). This strategy
minimizes early false priming and facilitates specific amplification
by low annealing temperature primers during later stages of the
program (26, 33). A nested or semi-nested approach was then ap-
plied wherein 1 ml of the first-round PCR reactions was reampli-
fied in fresh 25-ml second-round reactions using internal primers
(Table 1) with a repeat of the touchdown strategy. First-round
negative controls were also reamplified in the second-round to
exclude contamination. Second-round PCR reactions were sub-
jected to agarose electrophoresis and the products were harvested
and purified using QIAquickTM kits (Qiagen, Hilden, Germany).
Purified PCR products were sequenced directly using the
PCR and internal sequencing primers (Table 1) with dye termi-
nator cycle sequencing reagents (Applied Biosystems, Burwood,
Victoria, Australia) and analysis on a model 377 ABI automated
DNA sequencer. Both strands of each PCR product were se-
quenced using a total of 2–4 different primers (Table 1), thus ver-
ifying the methylation status of each cytosine residue in each ge-
nomic DNA strand 2–4 times.
Quantitative Competitive Reverse Transcriptase PCR Assay of Cy-
tokine mRNA Levels. Competitor plasmids bearing small dele-
tions in the IFN-g or IL-3 cDNAs were constructed as described
elsewhere. For IFN-g, the competitor lacks 82 bp around an in-
troduced XhoI site compared with the wild-type sequence. The
IL-3 competitor lacks 77 bp compared with the wild-type se-
quence. Construction integrity was verified by DNA sequencing.
For QCPCR standards, the competitor plasmids were adjusted to
equimolar amounts, serially diluted in 10 mM Tris HCl (pH 8.0),
0.1 mM EDTA, and 1 mg/ml tRNA, and stored in aliquots at
2708C.
25-ml QCPCR reactions comprising 0.3 U Red Hot poly-
merase with the supplied reaction buffer, 2 mM MgCl2, 200 mM
dNTPs, 10 mM of each PCR primer, competitor plasmid dilu-
tions, T cell cDNA, and paraffin oil were assembled in 96-well
plates (Becton Dickinson). Separate amplifications for IFN-g or
IL-3 were conducted using the primer pairs MIFNGIN59 and
MIFNGIN39 or MIL3IN59 and MIL3IN39 (34), respectively,
with each 39 primer biotinylated. Reactions were cycled using
one cycle of 948C for 4 min then 608C for 1 min and 728C for
1.5 min, followed by 39 cycles of 948C for 0.5 min then 608C for
1 min and 728C for 1.5 min. Each cDNA was tested against five-
fold competitor dilutions, ranging over seven (IFN-g) or five (IL-3)
orders of magnitude. To account for RNA extraction and cDNA
synthesis variations, separate determinations of the stimulus-resis-
tant T cell–specific CD3e mRNA (29, 35, 36) were used to cor-
rect the cytokine mRNA levels measured. Using these methods,
the correlation between clone size (30–300 cells) and CD3e
mRNA levels is routinely high (r .0.75).
Aliquots of QCPCR reactions were separated by electro-
phoresis to verify appropriate product sizes and estimate titration
equivalence points. Additional aliquots were tested by PCR-
ELISA (37) for hybridization with oligonucleotide probes specific
for the exogenous competitor products or the endogenous intact
cytokine cDNA products. In brief, the biotinylated PCR prod-
ucts were diluted in PBS/0.2% Tween 20 (PBST) then bound to
streptavidin-coated plates. The bound products were denatured with
50 mM NaOH/2 mM EDTA for 2 min, then incubated with 100
ng/ml FITC-labeled oligonucleotide probe diluted in 63 SSC,
20% formamide, and 1 mg/ml denatured fish sperm DNA for 16 h
at 428C. After four washes with PBST, bound probes were de-
tected with an alkaline phosphatase–conjugated antifluorescein
antibody (Boehringer Mannheim) followed by para-nitrophenol
colorimetric substrate development and spectrophotometric
ELISA read-out. The sensitivity of the QCPCR assay for IFN-g
and IL-3 mRNA was z100–500 input competitor molecules by
agarose electrophoresis and z20–100 input molecules by PCR-
ELISA. Amplification rates for the competitor and endogenous
PCR products were equivalent, semilogarithmic titration data
were linear over .3 orders of magnitude, and probe specificity
was high with negligible background or cross-reactivity (data not
shown). Accordingly, the competition equivalence points of the
exogenous competitor– and endogenous cDNA–derived PCR
products were virtually identical when determined by agarose
electrophoresis and PCR-ELISA. The equivalence point repro-
ducibility among assays of positive control samples was high, with
standard deviations ,15% of the means (data not shown).
Results
Potential Methylation Sites in the Mouse IFN-g and IL-3
Promoters. Sequence analysis revealed several, mostly clus-
tered, CpG methylation sites in the mouse IFN-g and IL-3
promoters within z300 bp of the transcription start site
(Fig. 1). Despite the low overall sequence conservation, 1–4
CpG sites z40–60 bases upstream of the transcription start
site, were present in both genes of all species. Several of the
CpG sites overlapped with the binding sites of transcription
factors shown to be involved in the regulation of human
IFN-g or IL-3 promoter activity. The binding of some of
these factors, including the cyclic AMP response element
binding protein (CREB) and ETS members, has been
shown to be directly affected by cytosine methylation (13,
23, 38). Of all these CpG sites in these two genes, only the
253 site in the IFN-g promoter has hitherto been charac-
terized for its methylation status in T cells (21, 22).
Inhibition of DNA Methylation Increases CD81 T Cell IFN-g
and IL-3 Secretion. The cytosine methylation inhibitor
5-azacytidine has previously been shown to increase the
expression of IFN-g in long-term T cell clones and lines
(21, 39). Given the similar pattern of potential methylation
sites in the mouse IFN-g and IL-3 promoters (Fig. 1), we
tested the effect of this inhibitor on IFN-g and IL-3 ex-
pression in primary mouse CD81 T cells activated in vitro
in a TCR-dependent, accessory cell–independent, solid-
phase mAb system. Treatment with 5-azacytidine increased107 Fitzpatrick et al.
IFN-g expression up to 25-fold and IL-3 expression up to
14-fold in a dose-dependent manner, with different dose
optima for the two cytokines (Fig. 2). Within the dose
range shown, T cell proliferation was unaffected but 5-aza-
cytidine doses .8 mM resulted in inhibition of prolifera-
tion and cell death and consequently cytokine levels below
those of untreated cultures (data not shown). Increased cy-
tokine secretion in the 5-azacytidine–treated cultures was
maximal on day 2 (IFN-g) or 3 (IL-3), with trends towards
plateau levels at day 3 or 4, respectively (Fig. 2). These ki-
netics represent an acceleration of the expression of IFN-g
and IL-3 in this culture system (27, 28). Thus, these results,
in support of the sequence analysis above, suggested a po-
tential role for DNA methylation in regulation of expres-
sion of both the IFN-g and IL-3 genes in primary mouse
CD81 T cells.
Bisulfite Genomic DNA Sequencing of the Mouse IFN-g and
IL-3 Promoters. To study comprehensively the potential
cytosine methylation sites in the mouse IFN-g and IL-3
promoters, we used bisulfite genomic DNA sequencing to
display the methylation status of all of the cytosines on both
DNA strands of the promoter regions analyzed (Figs. 1 and
3). In both genes, cytosines in a CpG sequence context
were virtually the only nonmodified (i.e., methylated) cy-
tosines detected. Methylation at CpNpG sites (40) was en-
countered at ,1% of all potential CpNpG sites and in
,5% of all samples. Consequently, .99% of non-CpG cy-
tosines exhibited cytosine to thymidine conversion, thus in-
ternally controlling for the efficiency of the bisulfite modi-
fication and for PCR and sequencing artifacts. Repeated
bisulfite modifications, PCR, and direct PCR product se-
quencing of control mixes of methylated and nonmethy-
lated molecules, similar to experiments reported previously
(25, 41), confirmed that this method reproducibly displays
the predominant methylation pattern of a heterogeneous
population of molecules (data not shown). Coincident clear
cytosine and thymidine peaks (Fig. 3), indicative of possible
mixed or transitional CpG methylation status, were seen at
a frequency of ,13% of the sites examined in the panel of
clones (see below). The methylation of CpG bps was usu-
ally symmetrical with identical patterns on the coding and
noncoding DNA strands in 80% of the sites tested. This re-
sult, derived from independent PCR reactions on separate
aliquots of modified genomic DNA from each clone, also
affirmed the reproducibility of the analyses. Symmetrical
methylation of all of the predicted CpG sites in the coding
and noncoding strands of the IFN-g and IL-3 promoters
was observed in the control mouse FDC-P1 myelomono-
cytic cell line that does not express IFN-g or IL-3 (42, 43),
Figure 1. Homology of CpG sites in the IFN-g (A) and IL-3 (B) genes
in different species. The mouse sequence is numbered relative to the tran-
scription start site (||555.). Marmoset (MARM), human, rat, and/or
rhesus monkey (RHES) sequences are also shown. The mouse sequence is
the reference for the alignments, determined using the FASTA program,
with identical residues (.) and gaps (–) indicated. CpG sites (upper case
and bold, and asterisked for the mouse sites), TATA motifs (1111),
and ATG start codons (###) are also indicated. Potential transcription
factor–binding sites defined for the human sequence are underscored and
annotated with the sequence element and/or transcription factor acro-
nyms.
Figure 2. 5-azacytidine treatment increases IFN-g and IL-3 secretion
by primary mouse CD81 T lymphocytes. CD81 T cells from normal
C57BL/6 mouse LNs were activated in low density in vitro cultures using
solid-phase mAb against CD3e, CD8, and LFA-1 in the presence of IL-2
and varying concentrations of 5-azacytidine for the indicated periods of
time. Cumulative secreted cytokine levels were quantitated by ELISA (A,
IFN-g) or reporter cell bioassay (B, IL-3). The results shown are repre-
sentative of three independent experiments.108 Differential IFN-g and IL-3 Gene Methylation in CD81 T Cells
Figure 3. Primary bisulfite genomic DNA sequencing data. Nuclear DNA from clonal cultures of primary mouse CD81 T cells was purified, bisulfite
modified, amplified, and sequenced directly using dye terminator chemistry and automated fluorescent sequence analysis. Sequence results for the non-
coding strands of the IFN-g promoter between bases 227 and 260 in four different clones are shown in the left panel. Sequence results for the noncod-
ing strands of the IL-3 promoter between bases 240 and 272 in three different clones are shown in the right panel. Methylated cytosines are displayed by
retained blue cytosine peaks while nonmethylated cytosines are converted by bisulfite modification and PCR to red thymidine peaks. These peaks were
scored for each clone and are shown below the chromatograms by the following symbols: j, methylated; h, demethylated. The presence of clear coin-
cident cytosine and thymidine peaks, e.g., at position 252 in the third IL-3 sequence, was scored: n, partially methylated.109 Fitzpatrick et al.
in bulk populations of normal nonstimulated spleen cells,
and in nonstimulated LN CD81 T cells (Fig. 4 and data not
shown).
Differential Methylation of the IFN-g and IL-3 Promoters in
Activated CD81 T Cells. Single CD81 T cells were cul-
tured with anti-CD3e, anti-CD8, and anti–LFA-1 mAbs in
the presence of IL-2 for 4–5 d, until clones of 32–256 cells
had formed. The methylation status of the IFN-g and IL-3
promoters in individual clones was then examined by
bisulfite genomic sequencing. In both the IFN-g and IL-3
promoters, clonal heterogeneity was seen with .30 distinct
patterns recorded in the panel of 40 clones (Fig. 4 and data
not shown). The methylation patterns in the two genes
were not related to each other or to clone size, which is an
approximation of division number. In the IFN-g pro-
moter, the patterns ranged from the two extremes of meth-
ylation of nearly all sites on the coding and noncoding
strands (e.g., Fig. 4, clone 1414), to demethylation of all 14
of these cytosines (e.g., Fig. 4, clone 1386). Contrastingly,
in the IL-3 promoter, demethylation of all sites was never
seen. Instead, site-specific differences predominated, rang-
ing from high-frequency demethylation of one or both of
the coding or noncoding strand cytosines at the 2164 CpG
site, to low-frequency demethylation of both cytosines at
the 252 site. In both the IFN-g and IL-3 genes, demethy-
lation of the CpG site immediately downstream of the
transcription start site was infrequent. It was concluded that
there was differential methylation of these two cytokine
genes in the same T cell clone, and that the methylation
patterns of the two genes were not closely related to clone
size. Therefore, these results were consistent with a clonally
variable, division-independent demethylation process, af-
fecting these two cytokine genes differentially.
Quantitation of Early IFN-g and IL-3 mRNA Expression in
Clonal Cultures of Activated Primary CD81 T cells. To dis-
close links between promoter methylation patterns and
transcriptional activity, the bisulfite genomic methylation
analysis above was coupled to QCPCR measurements of
cytokine mRNA levels. In this way, parallel steady state
genomic DNA and cytoplasmic mRNA data were derived
for each clone at the time of cell lysis.
The QCPCR results for the panel of clones showed that,
by 4-5 d of activation, approximately half of the clones had
detectable levels of IFN-g and/or IL-3 mRNA that ranged
over at least two (IL-3) or four (IFN-g) orders of magni-
tude (Fig. 5). The frequency of IFN-g mRNA expression
after 4–5 d was higher than that of IL-3 mRNA at these
early times. In comparison, clones in the 4–32 cell stage an-
alyzed after 2–3 d of stimulation expressed IFN-g mRNA
at a lower frequency, and IL-3 mRNA expression was usu-
ally undetectable (data not shown). Correlations between
mRNA levels and clone size (Fig. 5, A and B) were not
significant (r ,0.5). However, the probability of detection
of IFN-g or IL-3 mRNA was significantly higher in clones
larger than 256 cells, and clones with detectable IL-3
mRNA almost always coexpressed IFN-g mRNA (Fig. 5 C).
These data concurred with many of the previous re-
ported findings on the kinetics and relative levels of IFN-g
and IL-3 protein expression by primary mouse CD81 T
cell clones (27, 28, 44, 45), and supported the choice of this
time frame for study of primary CD81 T cells during an
early phase of in vitro development, when about half the
clones had initiated cytokine mRNA expression.
Regional Demethylation of the IFN-g Promoter Is Associated
with High-Level IFN-g mRNA Expression in Activated CD81
T Cells. Comparing the methylation and mRNA data for
individual clones revealed a striking overall association be-
tween demethylation of the IFN-g promoter and expres-
sion of mRNA (Fig. 6). Clones lacking detectable levels of
IFN-g mRNA exhibited relatively dense methylation of
8–13 of the CpG cytosines examined on the two DNA
strands of the IFN-g promoter. In contrast, the majority of
IFN-g mRNA-positive clones exhibited multiple and
sometimes uninterrupted demethylation of all CpG sites in
the IFN-g promoter between positions 2210 and 11. A
small number of clones (e.g., clones 1417, 1427, and 1408,
Fig. 6) expressed relatively low levels of IFN-g mRNA and
retained symmetrical or hemi-methylation of most of the
CpG sites.
Figure 4. Differential methylation of the IFN-g and IL-3 genes in
CD81 T cell clones and independence of clone size. CpG sites in the two
promoters are depicted schematically and numbered as described in Fig.
1. Asterisks above the 253 site in the IFN-g promoter indicate the only
CpG site hitherto characterized in T cells. Methylation of the coding (up-
per line of symbols) and noncoding (lower line of symbols) strands for the IFN-g
and IL-3 promoters are shown for the control cell line FDCP1 and 16
CD81 T cell clones ranging in size from 35 to .256 cells. Methylation
patterns were scored as described in Fig. 3.110 Differential IFN-g and IL-3 Gene Methylation in CD81 T Cells
Although these promoter-wide or regional demethyla-
tion patterns were pronounced, clone- and site-specific dif-
ferences across the IFN-g promoter were also evident. For
the panel as a whole, symmetrical or hemi-demethylation
of the 245 and 234 CpG sites occurred with the highest
frequency, whereas the site at position 117 exhibited the
lowest frequency of demethylation, yet the status of these
sites was not related to IFN-g mRNA levels. In contrast,
the 2205, 2191, and 253 CpG sites were symmetrically
methylated in most IFN-g mRNA-negative clones, and
their demethylation was closely correlated with expression
of .103 U of IFN-g mRNA. As shown in Fig. 1 A, these
three CpG sites are adjacent to conserved activator protein 1
Figure 5. Quantitation of IFN-g and IL-3 mRNA levels in a panel of
CD81 clones by competitive PCR after 4–5 d of stimulation. Levels of
mRNA were determined by QCPCR and corrected for CD3e mRNA
levels as described in Materials and Methods. A shows relative IFN-g
mRNA levels in relation to clone size. B shows relative IL-3 mRNA lev-
els in relation to clone size in the same set of clones. C shows the relation-
ship between IFN-g and IL-3 expression levels for each clone in the
panel. The results for 53 clones are shown.
Figure 6. Regional IFN-g promoter methylation patterns are related
to IFN-g mRNA expression levels in CD81 T cells. Clone sizes and me-
thylation patterns are shown as described in the legend to Fig. 4. Levels of
mRNA are also shown as described in the legend to Fig. 5. The results
depicted are representative of a panel of 40 clones for which complete
DNA and mRNA data were obtained. Clones with undetectable mRNA
levels are ranked by methylation pattern, whereas mRNA-positive clones
are ranked by mRNA level.111 Fitzpatrick et al.
(AP-1) and activating transcription factor (ATF)/CREB
transcription factor–binding sites.
Site-specific Demethylation of the IL-3 Promoter Is Associated
with IL-3 mRNA Expression in Activated CD81 T Cells.
In the same panel of CD81 T cell clones, the patterns of
DNA methylation and mRNA expression for IL-3 were
distinctly different from IFN-g. Although clones lacking
detectable levels of IL-3 mRNA again exhibited relatively
dense methylation of 8–12 of the CpG cytosines examined
on both strands of the IL-3 promoter from bases 2270 to
130, widespread demethylation of multiple CpG sites
across the IL-3 promoter was never seen (Fig. 7). Among
the IL-3 mRNA-negative clones, all of the CpG sites ex-
cept position 2164 exhibited high-frequency methylation.
In the IL-3 mRNA-positive clones, symmetrical demethy-
lation of the 2164 CpG site was frequent (10 out of 12
clones, or 83%) and was linked to a slightly higher fre-
quency of symmetrical or hemi-demethylation of the 262
CpG site. However, symmetrical demethylation of the
2164 CpG site in the IL-3 promoter also occurred in a
small proportion (6 out of 18, or 33%) of IL-3 mRNA-
negative clones. As shown in Fig. 1 B, the 2164 CpG site
abuts a GATA transcription factor–binding site that is not
conserved in primates, whereas the 262 site overlaps with
a partially conserved Sp1-binding site.
Heritability of IFN-g Promoter Methylation Patterns in
CD44 Subsets of CD81 T Cells. We have previously pre-
sented evidence for the inheritance of cytokine production
patterns in families of subclones of CD41 and CD81 T
cells from normal mice (27, 29). Therefore, we tested
whether the IFN-g gene methylation patterns and levels of
mRNA expression described above were heritable charac-
teristics of CD81 T cell clones, and whether this would
vary for T cells at different stages of in vivo differentiation.
To this end, LN cells from normal mice were sorted into
CD81CD44high or CD81CD44low subpopulations to enrich
for previously activated or resting T cells, respectively (46–
48). Single cell cultures were initiated as described above
and, after 4 d, the resultant parent clones were subcloned
by micromanipulation. Parent and progeny subclones were
harvested 2–3 d later, thus allowing clonal expansion for
two to six divisions under the stimulation conditions used.
Fig. 8 shows that, in families derived from CD44high
CD81 T cells, most of the CpG sites in the IFN-g pro-
moter were demethylated in all of the parent clones and
their subclones, all of which expressed high levels of IFN-g
mRNA. These results corroborated our earlier results on
the close association between regional promoter demethy-
lation and high IFN-g mRNA expression (Fig. 6), and are
consistent with the well-described augmented IFN-g ex-
pression status of CD44high T cells (49, 50). In contrast,
more variability in IFN-g gene methylation and expression
was seen among and within the families derived from
CD44low cells. Interestingly, this variability was less marked
for the CpG sites at positions 2205, 2191, and 253,
whose status was shown (Fig. 6 and see above) to correlate
most closely with IFN-g mRNA expression. As a result,
the previously determined relationships between methyla-
tion pattern and mRNA expression (Fig. 6) were largely
maintained in this panel. In addition, partial methylation at
certain sites was perpetuated in some related siblings. This
may reflect the maintenance of a balance between methyla-
tion and demethylation similar to a previously reported
phenomenon for the adenosine phosphoribosyltransferase
gene in a panel of teratocarcinoma stem cell lines (51).
These data indicate that demethylation of multiple sites
in the IFN-g promoter is different in clones derived from
the CD44high and CD44low subsets of mouse CD81 T cells,
and that these differences, in conjunction with quantita-
tively distinct levels of IFN-g expression, can be passed on
to the progeny of individual T cell clones.
Figure 7. Site-specific IL-3 promoter methylation patterns are related
to IL-3 mRNA expression levels in CD81 T cells. Clone sizes, methyla-
tion patterns, and mRNA levels for the panel of clones are shown as de-
scribed in the legend to Fig. 6.112 Differential IFN-g and IL-3 Gene Methylation in CD81 T Cells
Figure 8. Heritability of IFN-g promoter methylation patterns and IFN-g
mRNA expression levels in families of CD81 T cells. CD81 LN T cells from
normal mice were separated by FACSÒ into CD44low and CD44high subpopula-
tions, and seeded by automated deposition as single cells into stimulation cultures
for 4 d as described in Materials and Methods. Parental CD81 T cell clones were
then subcloned by micromanipulation, with harvesting of progeny subclones af-
ter 2–3 d of further growth. Families of clones derived from CD44low cells are
shown in A, whereas those derived from CD44high cells are shown in B. Each
family has a separate letter code with the parent clone (0) and sibling subclones
(1–6) numbered. The parent clone for family C did not survive micromanipula-
tion. Methylation patterns and mRNA levels for the families of clones are shown
as described in the legends to Figs. 4 and 5.113 Fitzpatrick et al.
Discussion
The above results demonstrate that cytokine gene meth-
ylation exhibits many of the features of a mechanism that
can regulate two T cell cytokine genes differentially, with
heterogeneity between individual T cell clones, and with
heritability in differentiated T cells with the CD44high phe-
notype. Therefore, these findings are germane to our un-
derstanding of the diversification of cytokine profiles in pri-
mary T cells, the maintenance of established cytokine
expression patterns in differentiated T cells, and the molec-
ular mechanisms involved in cytokine gene regulation.
This investigation was initiated upon finding that there
was remarkable similarity in the potential CpG methylation
sites of the mouse IFN-g and IL-3 promoters, and that
many of these sites overlapped with binding sites for tran-
scription factors known to be directly affected by CpG me-
thylation (Fig. 1; references 13, 38). These sequence-based
inferences were supported by experiments with the cytosine
methylation inhibitor 5-azacytidine, in which 5-azacyti-
dine increased and accelerated both IL-3 and IFN-g ex-
pression in bulk cultures of CD81 T cells (Fig. 2). This re-
sult confirms previously reported results for the effect of
5-azacytidine on IFN-g expression in long-term mouse
CD41 T cell clones or primary human CD41 T cells (21,
22), and extends them to both IFN-g and IL-3 in primary
mouse CD81 T cells.
However, 5-azacytidine is a toxic agent and it is difficult
to distinguish its direct methylation-mediated effects from
other indirect actions, particularly in proliferating poly-
clonal cell populations. It is also thought that it acts via di-
vision-dependent interference in maintenance methylation,
which is unlikely to resemble normal demethylation mech-
anisms (8, 9, 52). Therefore, we undertook experiments to
characterize IFN-g and IL-3 gene methylation, demethyla-
tion, and mRNA expression events as they occurred during
the in vitro development of cytokine-producing T cells.
Our approach incorporated use of (a) primary mouse
CD81 T cells analyzed during the early stages of growth
and cytokine expression; (b) solid-phase anti-CD3e, anti-
CD8, and anti–LFA-1 mAb to stimulate high frequencies
of T cells from normal mice in a TCR- and accessory mol-
ecule–dependent manner; (c) accessory cell–free conditions
to eliminate non–T cell sources of DNA and mRNA; (d)
clonal cultures to disclose the degree of heterogeneity ob-
scured in bulk culture studies, allow visual quantitation of
cell proliferation, and permit analyses of heritability by sub-
cloning; (e) bisulfite genomic DNA sequencing to map
comprehensively the sites of cytosine methylation on both
strands of the IFN-g and IL-3 promoters in small numbers
of cells; and (f) sensitive competitive PCR-based quantita-
tion of mRNA levels in small numbers of cells. This ap-
proach was thus designed to reveal the full range of cellular
and molecular potentialities of the primary developing
CD81 T cell clones under study.
Clonal heterogeneity, in the levels and combinations of
cytokines produced, is a prominent feature of cytokine ex-
pression in primary T cells (2, 4, 53). Broad heterogeneity
in IFN-g and IL-3 gene CpG methylation patterns was
seen in the panel of clones examined in this study (Figs. 4,
6, and 7). Indeed, when the methylation patterns of all the
sites in the two genes were considered together (e.g., Fig.
4), nearly every clone in the panel possessed a unique pat-
tern. These results showed that there was not a uniform
demethylation pathway or program for each gene in all
cells, or for two sequences with similar CpG arrays such as
the IFN-g and IL-3 promoters, even when both cytokines
were expressed (e.g., Figs. 6 and 7; clones 1383, 1412,
1415, and 1418). Instead, differential demethylation of the
two induced genes occurred in the same T cell clone. Nev-
ertheless, the methylation status of individual CpG sites
studied here was not entirely autonomous or independent
since apparent linkages between the status of neighboring
CpG sites in the IFN-g and IL-3 promoters were seen
(Figs. 6 and 7). This may, in part, reflect maintenance me-
thylase activity since this enzyme, while restoring symmet-
rical methylation to hemi-methylated CpG sites, has also
been found to initiate de novo methylation of neighboring
symmetrically nonmethylated CpG cytosines (54, 55).
Regional or site-specific demethylation of the IFN-g or
IL-3 promoters, respectively, was associated with different
levels of the mRNAs derived from these genes. In particu-
lar, there was a striking association between promoter-wide
demethylation of the IFN-g gene and expression of high
levels of IFN-g mRNA (Fig. 6). However, large differ-
ences in demethylation frequencies of CpG sites in IFN-g
mRNA-negative clones also occurred and revealed a subset
of CpG sites, including the previously characterized 253
site, whose methylation was closely associated with the ab-
sence of detectable IFN-g mRNA. Similarly, site-specific
effects in the IL-3 promoter were pronounced with most
of the demethylation activity focussed on the 2164 CpG
site, which was almost invariably demethylated in IL-3
mRNA-positive clones (Fig. 7). A small proportion of
clones possessing a demethylated 2164 CpG site lacked
detectable IL-3 mRNA, suggesting that demethylation at
this site may precede mRNA expression and/or that demeth-
ylation of this site alone may be either unnecessary or insuf-
ficient for IL-3 gene expression in some T cells.
Together, the above findings justify several levels of
studies required to elucidate the role of DNA methylation
in the regulation of cytokine gene expression in T cells.
The dissection of methylation-mediated regulatory mecha-
nisms is an intensely active field that is currently in a state
of flux, with many long-standing views being reconsidered
in light of unanticipated new information (10, 15, 52, 55).
We believe that similar reconsideration arises from com-
prehensive bisulfite sequencing methylation analysis of
clonal cultures of primary cells.
First, the above mapping in primary T cells of the site-
specific CpG differences that correlate with specific levels
of mRNA expression, and with known transcription factor
binding sites, has identified a revised set of sites and tran-
scription factors to be probed for direct methylation-depen-114 Differential IFN-g and IL-3 Gene Methylation in CD81 T Cells
dence. One study has been conducted for the 253 CpG
site in the human IFN-g promoter where methylation was
shown to affect directly the binding of the factors CREB,
ATF-2, and the c-jun component of AP-1 (23). The results
presented here indicate that similar studies are warranted
for the 2205 and 2191 CpG sites in the mouse IFN-g
promoter and the 2164 and 262 sites in the mouse IL-3
promoter. Moreover, the transcription factors to be assayed
can be provisionally extended to include two members of
the GATA family, YY1 (which can interact directly with
CREB and ATF members; reference 56) and Sp1. The fac-
tors YY1 and Sp1 are reportedly unaffected by CpG meth-
ylation in some sequence contexts (13, 38), but, to our
knowledge, the sensitivity of members of the GATA family
has not yet been reported. Conversely, recent description
of the unanticipated creation of an AP-1 factor–binding site
by CpG methylation within a nonconsensus AP-1 se-
quence (57) underlines the importance of further analyses
at this level.
Second, similar transcription factor–binding studies will
also need to be conducted in the presence or absence of
proteins such as MeCP2 and histone H1 (13, 14). These
well-characterized ubiquitous proteins can bind methylated
cytosines in any sequence context and indirectly inhibit
transcription factor–binding in a competitive manner or via
active repression (15). These effects are methylation density
dependent (58, 59) and compatible with the clustered dis-
tribution of the key CpG sites in the IFN-g and IL-3 pro-
moters.
The third level of studies requires analyses of the effect of
gene methylation on chromatin structure. Several recent
reports show that a medium to high density of methylated
CpG sites, in the presence of MeCP2 or histones, can pro-
mote the formation of a higher-order nucleosome-like
structure that is inaccessible to DNase I and is transcrip-
tionally silent (15, 60, 61). The regional patterns of methy-
lation and promoter-wide demethylation that we have de-
scribed here for the IFN-g promoter are also compatible
with the involvement of such a mechanism in the switch
between undetectable and high-level IFN-g mRNA ex-
pression.
The results of these three substantial levels of study will
determine to what extent DNA methylation-mediated
mechanisms are necessary and/or sufficient for regulation
of expression of different cytokine genes in T cells. More-
over, the results we have presented here suggest that con-
clusions on the necessity or sufficiency of individual mech-
anisms may need to be qualified according to the level of
gene expression and the phenotype of the T cell (see be-
low). The potential regulatory diversity arising from this
pretranscriptional/transcriptional level is likely to be great
given the differences described here between two cytokine
genes with similar CpG site densities and distributions, the
broad range of promoter CpG methylation patterns in
other cytokine genes expressed by T cells, and the possible
contributions from methylation in distant enhancer ele-
ments (reference 62 and Fitzpatrick, D.R., unpublished data).
Equally important is investigation of the pathways that
regulate methylation and demethylation processes. Two re-
ports have linked activation of the Ras signaling pathway to
DNA methylation or demethylation activities (63, 64), and
a role for the transcription factor NF-kB in demethylation
of the immunoglobulin k gene in a B cell line has also been
shown (65). Since the former pathway would tend to link
cytokine gene demethylation to activation of the TCR,
whereas the latter molecular mechanism may be more de-
pendent on costimulatory signals (66), it will be pivotal to
determine which signals are involved in the induction of
cytokine expression in T cells. We have recently shown
that activation of the extracellular signal-regulated kinase
branch of the Ras-activated cascade is required for maximal
TCR-mediated IFN-g and IL-3 expression in primary
mouse CD81 T cells (67, 68). Although these bulk culture
studies are not directly comparable to the clonal studies de-
scribed here, it will be interesting to determine whether
this signaling pathway exerts some of its downstream effects
through cytokine gene demethylation.
The importance of the above multi-faceted investiga-
tions is emphasized by the experiments herein, which char-
acterize the heritability of IFN-g methylation patterns and
mRNA expression levels in T cells at different stages of in
vivo differentiation: previously activated (also referred to as
memory/effector) CD44high cells and resting (or naive)
CD44low cells. In clones derived from CD44high T cells, re-
gional IFN-g promoter demethylation and high-level ex-
pression of IFN-g mRNA were inherited characteristics
shared by all parent and progeny clones. In contrast, in
clones derived from CD44low T cells, IFN-g gene methyla-
tion and expression patterns were variable both between
and within different families of clones. Therefore, over the
two to six cell division time frame of these studies, the
IFN-g promoter CpG methylation pattern and the fidelity
of its vertical transfer were closely associated with both the
initial surface marker phenotype of the parental T cells and
with the final IFN-g expression phenotype of both the par-
ent and progeny clones.
This result is germane to four sets of previously pub-
lished work. First, it confirms and extends the report that
the 253 CpG site in the human IFN-g promoter may
be preferentially demethylated in the recently activated
CD45RAlow/CD45ROhigh subset of primary human CD41
T cells (22). Second, it corroborates our previous findings
on similar kinetic patterns of GM-CSF and IL-3 expression
in the progeny of some CD41 T cells (27), and on the re-
tention of IFN-g mRNA expression by the progeny of
some CD81 T cells (29). Third, it compares favorably with
the previously described flexibility of resting or “naive”
CD44low T cells in contrast to the more restricted differen-
tiative potential of previously activated or “memory/effec-
tor” CD44high T cells (4, 29, 50). Fourth, it supports earlier
studies on the heritability of methylated CpG sites in long-
term cell lines transfected with plasmid or viral DNA (69,
70), and the variable fidelity of this process in some primary
cells (51, 71, 72). Our data add to each of these aspects by115 Fitzpatrick et al.
demonstrating differential short-term heritability of multi-
ple contiguous methylation sites in the IFN-g gene, an en-
dogenous induced gene, and linking this difference to the
surface marker phenotypes of two subpopulations of pri-
mary CD81 T lymphocytes.
Thus, differences in cytokine gene methylation represent
a molecular correlate of other well-characterized markers
of T cell differentiation. Whether these correlations are
preserved over longer periods and in vivo, for example
during antigen stimulation followed by a return to quies-
cence (48), merits additional study. Whether DNA methy-
lation can reflect, establish, and/or maintain the commit-
ment or reversibility of T cell cytokine expression patterns,
particularly under polarizing priming or restimulation con-
ditions (73), is also worthy of further investigation.
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